Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma Sponsors Chronic Fatigue Syndrome Conference at Mount Sinai Medical Center in New York

Globe Newswire November 19, 2013

Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2013

Globe Newswire November 8, 2013

Hemispherx Biopharma Reports on Annual Stockholder Meeting

Globe Newswire October 18, 2013

Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration

Globe Newswire October 3, 2013

Faruqi & Faruqi, LLP Launches An Investigation Against Hemispherx Biopharma, Inc. (HEB) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Business Wire September 20, 2013

Hemispherx Biopharma's 2013 Stockholder Annual Meeting Set

Globe Newswire September 18, 2013

Natural Human Interferon (Alpha-n3) is Active Against Both Wild-Type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus

Globe Newswire September 12, 2013

Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena

Globe Newswire September 12, 2013

Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat

Globe Newswire September 12, 2013

Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Potentially Reduce Pandemic Influenza Spread

Globe Newswire September 4, 2013

Hemispherx Biopharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th

Globe Newswire September 3, 2013

Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat

Globe Newswire August 26, 2013

Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread

Globe Newswire August 20, 2013

Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013

Globe Newswire August 9, 2013

Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee

Globe Newswire July 29, 2013

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013

Globe Newswire May 8, 2013

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012

Troy Schwensen March 18, 2013

Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina

Troy Schwensen March 4, 2013

U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous

Marketwired March 1, 2013

Rosen Law Firm Reminds Hemispherx Biopharma Investors of Important February 22, 2013 Deadline -- HEB

Troy Schwensen February 16, 2013